Immunyx Pharma is developing a first-in-class oral RAB27A inhibitor that reduces neutrophil-driven inflammation without impairing immunity. The dead asset, IMYX-3 shows strong preclinical efficacy in IBD and COPD and is advancing toward an IND in 2026. Partnering with top KOL advisors, and large markets lacking effective oral anti-inflammatories, Immunyx offers a differentiated, high-value clinical entry opportunity.